Nature Communications (Mar 2021)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

  • Jean-Sélim Driouich,
  • Maxime Cochin,
  • Guillaume Lingas,
  • Grégory Moureau,
  • Franck Touret,
  • Paul-Rémi Petit,
  • Géraldine Piorkowski,
  • Karine Barthélémy,
  • Caroline Laprie,
  • Bruno Coutard,
  • Jérémie Guedj,
  • Xavier de Lamballerie,
  • Caroline Solas,
  • Antoine Nougairède

DOI
https://doi.org/10.1038/s41467-021-21992-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Favipiravir has broad-spectrum antiviral activity against a variety of RNA viruses. Here the authors investigate the safety, pharmacokinetics and anti-SARS-CoV-2 efficacy of different drug dosage in the a Syrian hamster model of infection and, combined with genetic analyses, they show that Favipiravir at high doses decrease viral infectivity while inducing the emergence of mutations in viral genomes, decreasing fitness.